An increased ratio of interleukin-1 receptor antagonist to interleukin-1α in inflammatory skin diseases
Corresponding Author
T. Terui
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Tadashi Terui, Department of Dermatology, Tohoku University School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai 980-8574, Japan, Tel.: 81-22-717-7271; Fax: 81-22-717-7275, E-mail: [email protected]Search for more papers by this authorT. Hirao
Institute for Advanced Skin Research Inc., Yokohama, Japan
Search for more papers by this authorY. Sato
Institute for Advanced Skin Research Inc., Yokohama, Japan
Search for more papers by this authorT. Uesugi
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorM. Honda
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorM. Iguchi
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorN. Matsumura
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorK. Kudoh
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorS. Aiba
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorH. Tagami
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorCorresponding Author
T. Terui
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Tadashi Terui, Department of Dermatology, Tohoku University School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai 980-8574, Japan, Tel.: 81-22-717-7271; Fax: 81-22-717-7275, E-mail: [email protected]Search for more papers by this authorT. Hirao
Institute for Advanced Skin Research Inc., Yokohama, Japan
Search for more papers by this authorY. Sato
Institute for Advanced Skin Research Inc., Yokohama, Japan
Search for more papers by this authorT. Uesugi
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorM. Honda
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorM. Iguchi
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorN. Matsumura
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorK. Kudoh
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorS. Aiba
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorH. Tagami
Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan, and
Search for more papers by this authorAbstract
Abstract: IL-1 receptor antagonist (IL-1ra) is a cytokine that competitively binds the IL-1 receptor to antagonize IL-1 activity without any agonist function. Previous experiments indicated that the ratio of IL-1ra to IL-1α in the normal stratum corneum (SC) was much higher in the sunexposed face than in the sun-protected area, upper arms. It was also reported by another laboratory that IL-1ra is increased in the lesional skin of psoriatic patients. This study was designed to measure the contents of IL-1α and IL-1ra in non-lesional and pathological SC obtained from inflammatory skin diseases including psoriasis and non-psoriatic dermatoses such as atopic dermatitis. The SC materials were obtained with a noninvasive tape-stripping method. Their soluble fractions were prepared and assayed for IL-1α and IL-1ra by enzyme-linked immunosorbent assays. As a result we confirmed the previous findings that the ratio of IL-1ra to IL-1α in the normal SC was much higher in the face than in the sun-protected sites, the trunk as well as extremities. Next, we found that IL-1α contents were significantly reduced in the SC samples obtained from inflammatory skin regardless of whether their IL-1ra contents increased or unchanged. Moreover, we noted that an increased ratio of IL-1ra to IL-1α in the SC was not specific to psoriasis, but was also found in other inflammatory skin diseases including atopic dermatitis. This ratio was found to become lower after successful treatment of these skin lesions with topical glucocorticoids. We conclude from these observations that the increased ratio of IL-1ra to IL-1α in the SC is a non-specific phenomenon that can occur in any inflammatory skin diseases regardless of the inflammatory pattern, probably reflecting a skin regulation process against various kinds of inflammation.
References
- 1 Eisenberg S P., Evans R J., Arend W P. et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990: 343: 341–346.
- 2 Dinarello C A.. Blocking IL-1: interleukin 1 and interleukin-1 antagonism. Blood 1991: 77: 1627–1652.
- 3 Haskill S., Martin G., van Le L. et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 1991: 88: 3681–3685.
- 4 Bigler C F., Norris D A., Weston W L. et al. Interleukin-1 receptor antagonist production by human keratinocytes. J Invest Dermatol 1992: 98: 38–44.
- 5 Gruaz-Chatellard D., Baumberger C., Saurat J H.. Interleukin 1 receptor antagonist in human epidermis and cultured keratinocytes. FEBS Lett 1991: 294: 137–140.
- 6 Terui T., Ishii K., Ozawa M. et al. C3 production of cultured human epidermal keratinocytes is enhanced by IFN-γ and TNF-α through different pathways. J Invest Dermatol 1997: 108: 62–67.
- 7 Kupper T S., Ballard D W., Chua A O.. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1α and β mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med 1986: 164: 2095–2100.
- 8 Gahring L C., Buckley A., Daynes R A.. Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human SC. J Clin Invest 1985: 76: 1585–1591.
- 9 Takematsu H., Suzuki R., Tagami H. et al. Interleukin-1-like activity in horny layer extracts: Decreased activity in scale extracts of psoriasis and sterile pustular dermatoses. Dermatologica 1986: 172: 236–240.
- 10 Terui T., Suzuki R., Kumagai K. et al. Absence of IL-1 inhibitor in psoriatic scale extracts. Tohoku J Exp Med 1988: 156: 149–156.
- 11 Kupper T S.. The activated keratinocyte: A model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses. J Invest Dermatol 1990: 94: 146s–150s.
- 12 Dripps D J., Brandhuber B J., Thompson R C., Eisenberg S P.. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991: 266: 10331–10336.
- 13 Granowitz E V., Clark B D., Mancilla J., Dinarello C A.. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991: 266: 14147–14150.
- 14 Romero L I., Ikejima T., Pincus S H.. In situ localization of interleukin-1 in normal and psoriatic skin. J Invest Dermatol 1989: 3: 518–522.
- 15 Hammerberg C., Arend W P., Fisher G L. et al. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992: 90: 571–583.
- 16 Kristensen M., Deleuran B., Eedy D J. et al. Distribution of interleukin-1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin-1α in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 1992: 127: 305–311.
- 17 Murphy G M., Dowd P M., Hudspith B N. et al. Local increase in interleukin-1-like activity following UVB irradiation of human skin in vivo. Photodermatology 1989: 6: 268–274.
- 18 Garmyn M., Yaar M., Boileau N. et al. Effect of aging and habitual sun exposure on the genetic response of cultured human keratinocytes to solar-stimulated irradiation. J Invest Dermatol 1992: 99: 743–748.
- 19 Hirao T., Aoki H., Yoshida T. et al. Elevation of interleukin 1 receptor antagonist in the SC of sun-exposed and ultraviolet B-irradiated human skin. J Invest Dermatol 1996: 106: 1102–1107.
- 20 Hirao T., Aoki H., Ichikawa H. et al. Characterization of an interleukin 1 receptor antagonist protein released from ultraviolet-irradiated epidermal sheet. J Dermatol Sci 1997: 14: 189–198.
- 21 Horii I., Nakayama Y., Obata M. et al. SC hydration and amino acid content in xerotic skin. Br J Dermatol 1989: 121: 587–592.
- 22 Bradford M M.. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976: 72: 248–254.
- 23 Cooper K D., Hammerberg C., Baadsgaard O. et al. IL-1 activity is reduced in psoriatic skin: decreased IL-1α and increased nonfunctional IL-1β. J Immunol 1990: 144: 4593–4603.
- 24 Mizutani H., Black R., Kupper T S.. Human keratinocytes produce but do not process prointerleukin-1 beta: different strategies of IL-1 production and processing in monocytes and keratinocytes. J Clin Invest 1991: 87: 1066–1071.
- 25 Nylander-Lundqvist E N., Egelrud T. Biologically active, alternatively processed interleukin-1β in psoriatic scales. Eur J Immunol 1997: 27: 2165–2171.
- 26 Debets R., Hegmans J P., Croughs P. et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997: 158: 2955–2963.
- 27 Krzesicki R F., Hatfield C A., Bienkowski M J. et al. Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts. J Immunol 1993: 150: 4008–4018.
- 28 McColl S R., Paquin R., Menard C. et al. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony stimulating factor and tumor necrosis factor α. J Exp Med 1992: 176: 593–598.
- 29 Arend W P., Smith M F. Jr, Janson R W. et al. IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J Immunol 1991: 147: 1530–1536.
- 30 Janson R W., Hance K R., Arend W P.. Production of IL-1 receptor antagonist by human in vitro-derived macrophages. J Immunol 1991: 147: 4218–4223.
- 31 Lennard A., Gorman P., Carrier M. et al. Cloning and chromosome mapping of the human interleukin-1 receptor antagonist gene. Cytokine 1992: 4: 83–89.
- 32 Smith M F. Jr, Eidlen D., Brewer M T. et al. Human IL-1 receptor antagonist promoter: cell type-specific activity and identification of regulatory regions. J Immunol 1992: 149: 2000–2007.
- 33 Smith M F. Jr, Eidlen D., Arend W P. et al. LPS-induced expression of the human IL-1 receptor antagonist gene is controlled by multiple interacting promoter elements. J Immunol 1994: 153: 3584–3593.
- 34 Butcher C., Steinkasserer A., Tejura S. et al. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol 1994: 153: 701–711.
- 35 Muzio M., Polentarutti N., Sironi M. et al. Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med 1995: 182: 623–628.
- 36 Turner M., Chantry D., Katsikis P. et al. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-β. Eur J Immunol 1991: 21: 1635–1639.
- 37 Orino E., Sone S., Nii A. et al. IL-4 up-regulates IL-1 receptor antagonist gene expression and its production in human blood monocytes. J Immunol 1992: 149: 925–931.
- 38 Vannier E., Miller L C., Dinarello C A.. Coordinated anti-inflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992: 89: 4076–4080.
- 39 Tilg H., Mier J W., Vogel W. et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993: 150: 4687–4692.
- 40 Ruth J H., Bienkowski M., Warmington K S. et al. IL-1 receptor antagonist (IL-1ra) expression, function, and cytokine-mediated regulation during mycobacterial and schistosomal antigen-elicited granuloma formation. J Immunol 1996: 156: 2503–2509.
- 41 Kutsch C L., Norris D A., Arend W P.. Tumor necrosis factor-α induces interleukin-1α and interleukin-1 receptor antagonist production by cultured human keratinocytes. J Invest Dermatol 1993: 101: 79–85.